Benzodiazepines are prescription medications commonly used to treat anxiety, insomnia, panic disorders, seizures, and muscle spasms. [1] Drugs such as Xanax, Ativan, Klonopin, and Valium work by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter (chemical messenger) that helps calm activity in the central nervous system (CNS), which refers to the brain and spinal cord. While these medications can provide short-term relief, long-term use may lead to tolerance, physical dependence, and addiction.
For many people, withdrawal from benzodiazepines becomes increasingly difficult over time. One reason is a neurological process known as the benzodiazepine kindling effect. This condition occurs when repeated withdrawal episodes cause the nervous system to become more sensitive, resulting in worsening withdrawal symptoms during future attempts to stop using the drug.
Although kindling is widely documented in alcohol withdrawal research, it is less recognized in conversations about benzodiazepines. Still, many individuals experience repeated benzodiazepine withdrawal effects that become more severe with each cycle of stopping use, restarting these medications, and stopping again. [2]
Understanding how the kindling effect affects the brain may help people make safer decisions about tapering, detoxification, and ongoing treatment for benzodiazepine addiction. It may also help reduce shame by showing that worsening withdrawal symptoms are rooted in neurobiology rather than personal weakness.
Over time, the brain adapts to regular benzodiazepine use. As GABA activity is repeatedly enhanced, the brain may reduce its natural inhibitory responses while increasing excitatory chemical activity involving glutamate. This process contributes to tolerance, meaning a person may need higher doses to achieve the same effect.
Dependence develops when the body becomes accustomed to the medication and struggles to function normally without it. [3] If benzodiazepines are stopped too quickly, the nervous system can become overstimulated, leading to withdrawal symptoms that range from uncomfortable to life-threatening.
Common withdrawal symptoms include:
Repeated withdrawal from sedative medications may contribute to sensitization within the nervous system, increasing symptom severity during future episodes of withdrawal.
It is important to distinguish tolerance from kindling. Tolerance refers to needing more of a substance to achieve the same effects. [4] Kindling refers to worsening withdrawal symptoms during repeated attempts to stop.
One reason withdrawal symptoms worsen is that repeated cycles of use and withdrawal sensitize the nervous system.
Chronic benzodiazepine exposure affects the balance between the brain’s calming chemical activity (GABA) and stimulating chemical activity (glutamate). [5] During withdrawal, glutamate activity can rebound dramatically, contributing to an overstimulated CNS.
Animal studies suggest that repeated withdrawals may lead to lasting changes in receptors associated with anxiety and seizure regulation. Researchers believe these alterations play a central role in the kindling effect.
Some people intermittently use benzodiazepines for sleep or anxiety relief. Unfortunately, repeated short-term exposure followed by abrupt cessation may still contribute to kindling. Short-acting medications such as Xanax may increase this risk because withdrawal symptoms can emerge very quickly between doses.
As glutamate activity increases, the nervous system can enter a hyperaroused state. During withdrawal, this may contribute to panic attacks, tremors, rapid heartbeat, and seizures. In some cases, repeated withdrawal may contribute to excitotoxicity, which refers to nerve cell damage caused by excessive stimulation.
Kindled withdrawal places significant stress on the autonomic nervous system, which regulates involuntary functions like heart rate and breathing. Severe withdrawal may increase the risk of:
With medical supervision, it is possible to prevent the kindling effect by using some prevention strategies:
Current evidence suggests that some neurological changes associated with kindling may not fully resolve. [6] However, the brain possesses neuroplasticity, which is the ability to reorganize and form new neural connections. With sustained abstinence and supportive care, nervous system stability typically improves.
Supportive management includes:
Kindling is a neurological process in which repeated benzodiazepine withdrawal episodes lead to increasingly severe withdrawal symptoms, such as intense anxiety, tremors, and a higher risk of seizures.
Yes. Even intermittent use can contribute to kindling if the medication is repeatedly started and stopped, as each cycle sensitizes the nervous system.
While some changes may persist, many people experience significant gradual improvement over time through abstinence, structured treatment, and professional support.
Yes. Tapering off benzodiazepine use is key. There are also drugs used to help manage the uncomfortable symptoms of benzodiazepine withdrawal. Experienced professionals and clinicians at Ascendant NY can help determine the best treatment plan for you.
Understanding the kindling effect helps individuals make informed decisions about tapering and recovery. With slow tapering and medically supervised care, healing is possible. You do not have to navigate this journey alone. If you or someone you know is struggling with kindling or benzodiazepine abuse, the caring professionals at Ascendant NY can help you take the next step towards healing.
Here at Ascendant New York, we understand the importance of having access to accurate medical information you can trust, especially when you or a loved one is suffering from addiction. Find out more on our policy.
[1] Figg, J. W., Love, C. A., Sorathia, V., Engelbart, M., Turner, A., & Elton, A. (2025). Benzodiazepines at the crossroads: Navigating therapeutic promise and perils of misuse. Addiction Science & Clinical Practice, 20(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC12879474
[2] Maviglia, M., Cooeyate, N., Hume, D., & Guerra, L. (2024). Kindling in psychopharmacology: Unveiling an overlooked clinical challenge with significant implications. Journal of Psychology & Clinical Psychiatry, 15(5). https://medcraveonline.com/JPCPY/JPCPY-15-00793.pdf
[3] Kosten, T. R., & O’Connor, P. G. (2003). GABA systems, benzodiazepines, and substance dependence. Journal of Clinical Psychiatry, 64(Suppl 3), 11-17. https://www.psychiatrist.com/pdf/gaba-systems-benzodiazepines-and-substance-dependence-pdf/
[4] Benzodiazepine Information Coalition. (2024, December 30). Tolerance – Benzodiazepine Information Coalition. https://www.benzoinfo.com/tolerance/
[5] [6] Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., … & Kaye, A. M. (2021). Benzodiazepines: Uses, dangers, and clinical considerations. Neurology International, 13(4), 594-607. https://www.mdpi.com/2035-8377/13/4/59